SIR -Neurons communicate with each other through synaptic connections, and short-term and long-term plasticity of synaptic transmission is believed to be an important cellular basis of learning and memory. Synaptic transmission is conducted by neurotransmitters released from presynaptic nerve terminals by exocytosis of synaptic vesicle contents. Various protein kinases as well as a lipid kinase such as PI-3 kinase have been shown to enhance neurotransmitter release in various neuronal preparations. Generally, all regulatory systems have a set of both positive and negative regulators. For example, we can drive a car safely by controlling the accelerator and the brake properly. However, no protein kinases involved in negative regulation have been reported so far. Recently, we found that two types of non-receptor protein tyrosine kinases are negative regulators of neurotransmitter release. [1] [2] [3] Src family kinases (SFK) are non-receptor tyrosine kinases and 10 different members have been identified so far. 4 Among these, Src is accumulated in synaptic vesicles and accounts for the majority of synaptic vesicle tyrosine kinase activity, however, its functional roles have not been clarified. We found that pretreating cells with SFK inhibitors extensively enhanced Ca 2+ -dependent dopamine (DA) release from clonal rat pheochromocytoma PC12 cells.
3 PC12 cells release DA by Ca 2+ -dependent exocytosis of secretory vesicle contents. Transient expression of constitutively active vSrc suppressed Ca 2+ -dependent exocytosis in an activity-dependent manner. DA release induced by Ca 2+ ionophore was also affected by these treatments, indicating that certain steps downstream from Ca JAK2 is another non-receptor tyrosine kinase associated with various cytokine receptors. 5 The haematopoietic growth factor erythropoietin (EPO) is a primary regulator of mammalian erythropoiesis and is produced by kidney and liver in an oxygen-dependent manner. 6 EPO and EPO receptors are also expressed in mammalian brain and believed to play a neuroprotective role in hypoxia. 7 We found that EPO receptor agonists induced activation of JAK2, and a concomitant suppression of Ca 2+ ionophore-induced neurotransmitter release from PC12 cells and central neurons. 1, 2 The onset of inhibition occurs very rapidly and inhibition is attenuated by a tyrosine kinase inhibitor, suggesting that JAK2-mediated tyrosine phosphorylation is involved in regulation. All of these results suggest that non-receptor tyrosine kinases act as negative regulators of presynaptic functions. In some cases, neurons need to depress synaptic functions. Habituation is a decrease in the strength of a behavioral response that occurs when an initially novel eliciting stimulus is repeatedly represented. Repeated stimulation of Aplysia sensory neurons resulted in the reduction of neurotransmitter release at the synapse afferent to motor neurons. 8 In mammalian brain, there is accumulating evidence for the existence of silent synapses, and transition between silent and active states is one of the mechanisms of synaptic plasticity. Two types of silent synapses may exist, one is the 'mute' synapse unable to exocytose synaptic vesicles, and the other is the 'deaf' synapse lacking in neurotransmitter sensitivity. 9 It is possible that non-receptor tyrosine kinases participate in habituation and in the creation of mute synapses to erase unnecessary information.
Negative regulation of neurotransmitter release is also important for neuroprotection. Glutamate is released in the course of brain ischemia and induces delayed neuronal cell death, especially in the CA1 region of the hippocampus, by cytoplasmic Ca 2+ overload through the overstimulation of NMDA glutamate receptors. 10 In chemical ischemia, glutamate is released by at least two distinct mechanisms: exocytotic and non-exocytotic. EMP1, a synthetic EPO receptor agonist, inhibits exocytotic glutamate release in a tyrosine kinase-dependent manner. 2 In hippocampal slice cultures, a brief chemical ischemic treatment induced neuronal cell death in the CA1 region and the dentate gyrus, which was suppressed by EMP1. Since EMP1 did not attenuate neuronal cell death induced by exogenously applied glutamate, neuroprotection must occur by the negative regulation of glutamate release. EPO also exerts its neuroprotective effect by postsynaptic mechanisms, and RNA and protein synthesis are necessary for these effects. 7 Thus, the activation of EPO-R seems to protect neurons from ischemic damage through multiple mechanisms, and negative regulation of neurotransmitter release seems to play an important role in neuroprotection.
Neurotransmitter release is a complex phenomenon and occurs in several steps, all of which may be modified by protein tyrosine phosphorylation. Since the effects of non-receptor tyrosine kinases appear very quickly, the suppression of neurotransmitter release seems to occur not by transcriptional or translational control but by tyrosine phosphorylation of existing proteins. [1] [2] [3] The intracellular localization of Src and JAK2 is different, the former is associated with the synaptic vesicle membrane and the latter is attached to cytokine receptors in the plasma membrane. Thus, it is possible these two kinases regulate transmitter release by phosphorylating different protein substrates. Synaptophysin, a synaptic vesicle protein, is phosphorylated by Src in vitro but we did not detect significant tyrosine phosphorylation of synaptophysin in PC12 cells. 3 SFK inhibitor-treatment causes a reduction of tyrosine phosphorylation of Pyk2 and paxillin, which are involved in regulation of the actin cytosketeton, and leads to a dramatic change in morphology of PC12 cells. Interestingly, inhibition of actin polymerization with Cytochalasin D and Latrunculin A enhanced Ca 2+ -dependent neurotransmitter release from PC12 cells and cultured rat cerebellar granule cells. It is thus possible that Src kinase suppresses neurotransmitter release by regulating cytoskeletal dynamics. The protein substrate essential for the JAK2-mediated inhibition has not yet been identified. The activity of Src and JAK2 are regulated through tyrosine phosphorylation. Furthermore, JAK2 phosphorylates tyrosine residues in the cytokine receptor, which can recruit and activate Src through the binding of an SH2 domain to phosphotyrosine.
5 Thus, it is also possible that JAK and Src mediate inhibition via common signal transduction pathways.
Many kinds of receptor tyrosine kinases are expressed in brain and the activation of these receptors stimulates neurotransmitter release in a tyrosine kinase-dependent manner.
11 Downstream signaling pathways including PI-3 kinase, MAP kinase and PLC are essential for positive regulation by receptor tyrosine kinases. It is quite interesting that the receptor tyrosine kinases and the non-receptor tyrosine kinases have opposite roles at presynaptic sites. But it is also a mystery since the downstream signaling pathways of receptor tyrosine kinases are also activated by JAK2-associated cytokine receptors. Furthermore, receptor tyrosine kinases can activate Src in some preparations. Many new questions must now be addressed in future studies to understand the molecular mechanisms and physiological roles of Src-and JAK2-mediated negative regulation of presynaptic functions in the nervous system. 3 have provided further evidence for an association between the DRD4 exon III 7 repeat allele and higher scores in Novelty Seeking, a number of studies failed to replicate the initial findings. 4 A recently identified single nucleotide polymorphism (−521C/T) in the promoter region of the DRD4 gene, 5 which is associated with variation in transcriptional efficiency, has also been reported to affect individual differences in Novelty Seeking. 5, 6 In these studies, the presence of the T allele (resulting in reduced transcriptional efficiency) was associated with significantly lower scores in Novelty Seeking. The aim of the present study was an investigation whether both the DRD4 exon III and the DRD4 −521C/T polymorphism are associated with individual differences in Novelty Seeking.
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Two hundred and seventy-six unrelated healthy volunteers of German ethnicity (205 women and 71 men; mean age: 21.9 ± 3.9 years, age range: 18-41 years) completed the German version of the Tridimensional Personality Questionnaire, 7 and individual DRD4 exon III genotypes were determined as previously described. 1 For determination of DRD4 −521 C/T genotypes, oligonucleotide primers (DRD4/627F, 5Ј-CGGGGGCTGAGCACCAGAGGCTGCT and DRD4/343R, 5Ј-GCATCGACGCCAGCGCCATCCTACC) were used to generate a 285-bp fragment. PCR amplification was performed for 37 cycles at 60°C (45 s), 72°C (45 s), and 95°C (45 s) in a final volume of 25 l containing 100 ng of genomic DNA, 20 pmol of each primer, 200 M of each dNTP, 1.0 mM MgCl 2 , 50 mM KCl, 10 mM Tris HCl (pH 8.3 at 25°C), 0.025 mg ml −1 BSA, 0.025% Tween 20, and 0.5 U of Taq DNA polymerase (Eurogentec, Seraing, Belgium). PCR products were analysed by FspI digestion followed by separation of the resulting fragments on agarose gels containing 2% ethidium bromide next to a DNA size standard. The two polymorphisms were in significant linkage disequilibrium (DЈ = 0.20, P = 0.005; calculation performed with 2LD, http://www.iop.kcl.ac.uk/IoP/ Departments/Psych Med/GEpiBSt/software.stm).
Analysis of variance showed that individuals with and without the DRD4 exon III 7 repeat did not differ in their Novelty Seeking scores (F 1,274 = 1.28, P = 0.26; for raw mean scores ± SD see Table 1 ). Similar results
